

 AP-USDR06	Site	<input type="text"/>	Subject	<input type="text"/>	Initials	<input type="text"/>	
	Visit Date	<input type="text"/>	<input type="text"/>	<input type="text"/>	Screening		Page 1
		Day	Month	Year			

INFORMED CONSENT			
Date the Informed Consent Form was signed by the subject:	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Day	Month	Year

DEMOGRAPHY			
Date of Birth:	<input type="text"/>	<input type="text"/>	<input type="text"/>
	Day	Month	Year
Gender:	<input type="radio"/> Male <input type="radio"/> Female		
Race:	<input type="radio"/> Caucasian <input type="radio"/> Black <input type="radio"/> Asian <input type="radio"/> Hispanic		
<input type="radio"/> Other (specify)	<input type="text"/>		

INCLUSION CRITERIA			
Patients who meet all of the following criteria are to be enrolled in the study:	YES	NO	N/A
1. Males or females > 18 years and < 80 years.	<input type="radio"/>	<input type="radio"/>	
2. Mean SeSBP \geq 150 mmHg and \leq 179 mmHg and a mean SeDBP \leq 105 mmHg at qualifying visits (Visits 3 and 4 OR Visits 4 and 4X) and a mean daytime ambulatory SBP (8AM-4PM) of \geq 140 mmHg and \leq 179 mmHg at Visit 4 (or Visit 4X). In addition, the difference between the mean SeSBP at two consecutive visits (Visits 3 and 4 OR Visits 4 and 4X) must be \leq 10 mmHg.	<input type="radio"/>	<input type="radio"/>	
3. Patients not taking antihypertensive medication or patients uncontrolled on antihypertensive therapy at screening. Uncontrolled on antihypertensive therapy is defined as any patient on antihypertensive therapy and who has a mean SeSBP \geq 140 mmHg and/or a mean SeDBP \geq 90 mmHg at the screening visit.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
4. Women of childbearing potential who have a negative urine pregnancy test at Visit 4A prior to randomization and at the end of the study or when the patient exits the study early. Furthermore, they must be using a medically accepted method of birth control (i.e., oral, parenteral or implanted contraceptive for at least one month prior to study entry; or spermicidal plus barrier methods) and agree to continue to use their present method of birth control throughout the study.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
5. Willing and able to sign informed consent.	<input type="radio"/>	<input type="radio"/>	

